18 February 2009

A new stimulator of hematopoietic function is looking for investors

Novosibirsk scientists have created a medicine for the treatment of blood diseases

Roszdravnadzor has registered a new drug for the treatment of blood diseases, created by scientists of the Novosibirsk State Scientific Center of Virology and Biotechnology (SSC WB) "Vector". The new drug, work on which began in the mid-1990s, and preclinical and clinical trials were conducted for six years, was called "Neutrostim". It is based on the granulocyte protein, a colony-stimulating factor that is produced by the body and regulates the process of hematopoiesis. This protein stimulates the formation of neutrophils by the bone marrow – white blood cells, with the help of which a barrier is created for viral and bacterial pathogens. The level of neutrophils decreases in a number of viral infections, in particular HIV, as well as in the treatment of cancer patients with radiation therapy and chemotherapy. In such cases, the time between courses is lengthened until the level of neutrophils in the blood is restored. "Neutrostim" helps to restore this level faster.

Currently, there are several similar drugs on the market. These are the Swiss "Neupogen" and the domestic drug "Leucostim". According to Valentina Masycheva, director of the Institute of Medical Biotechnology of the World Health Center "Vector", positive differences of the new drug can be noted. "Compared to Leucostim, its specific activity is higher, and unlike Neupogen, it does not affect red blood cells," she said. In addition, there is reason to believe that the new drug will be cheaper than analogues, one dose of which costs at least 4.5 thousand rubles. At the same time, for example, according to the treatment regimen, six or more doses may be required between courses of chemotherapy.

Vector, being a state scientific institution, cannot engage in the industrial production of pharmaceutical products, therefore, negotiations are underway with private pharmaceutical companies to bring the drug to the market. The volume of necessary investments is estimated at $ 5 million, ITAR-TASS clarifies.

News of SciencePortal "Eternal youth" www.vechnayamolodost.ru


Found a typo? Select it and press ctrl + enter Print version